98%
921
2 minutes
20
Hypertrophic cardiomyopathy (HCM) is one of the most common hereditary heart diseases and can be classified into an obstructive (HOCM) and non-obstructive (HNCM) form. Major characteristics for HCM are the hypertrophy of cardiomyocytes and development of cardiac fibrosis. Patients with HCM have a higher risk for sudden cardiac death compared to a healthy population. In the present study, we investigated the abundancy of selected proteins as potential biomarkers in patients with HCM. We included 60 patients with HCM and 28 healthy controls and quantitatively measured the rate of a set of 92 proteins already known to be associated with cardiometabolic processes via protein screening using the proximity extension assay technology in a subgroup of these patients (20 HCM and 10 healthy controls). After validation of four hits in the whole cohort of patients consisting of 88 individuals (60 HCM patients, 28 healthy controls) we found only one candidate, c-KIT, which was regulated significantly different between HCM patients and healthy controls and thus was chosen for further analyses. c-KIT is a tyrosine-protein kinase acting as receptor for the stem cell factor and activating several pathways essential for cell proliferation and survival, hematopoiesis, gametogenesis and melanogenesis. Serum protein levels of c-KIT were significantly lower in patients with HCM than in healthy controls, even after adjusting for confounding factors age and sex. In addition, c-KIT levels in human cardiac tissue of patients with HOCM were significant higher compared to controls indicating high levels of c-KIT in fibrotic myocardium. Furthermore, c-KIT concentration in serum significantly correlated with left ventricular end-diastolic diameter in HOCM, but not HCM patients. The present data suggest c-KIT as a novel biomarker differentiating between patients with HCM and healthy population and might provide further functional insights into fibrosis-related processes of HOCM.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815737 | PMC |
http://dx.doi.org/10.1038/s41598-020-80868-z | DOI Listing |
Cureus
August 2025
Medicine/Cardiology, Madigan Army Medical Center, Tacoma, USA.
Apical hypertrophic cardiomyopathy (ApHCM) is an uncommon, nonobstructive form of hypertrophic cardiomyopathy (HCM) that is associated with an increased risk of ventricular aneurysms, atrial fibrillation, heart failure, and cardiac death. In this case report, a 63-year-old male patient was found to have deeply negative T waves on electrocardiogram (EKG) during a routine preoperative evaluation in an outpatient internal medicine clinic. Imaging with echocardiography and cardiac magnetic resonance confirmed the diagnosis of ApHCM.
View Article and Find Full Text PDFFront Cardiovasc Med
August 2025
Department of Cardiology, Dongguan Tai-xin Hospital, Dongguan, China.
Objective: This study sought to identify key prognostic factors in patients with hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), emphasizing the prognostic role of free triiodothyronine (FT3) levels.
Research Design And Methods: This retrospective cohort study enrolled 992 HCM-HFpEF patients from two Chinese medical centers between 2009 and 2019, excluding those with thyroid-affecting medications or disorders. Data on demographic and clinical variables, including FT3, were analyzed using univariate and multivariate Cox regression, Kaplan-Meier (KM) survival analysis, and restricted cubic spline (RCS) analysis to explore prognostic factors and FT3's nonlinear predictive value.
Cardiovasc Endocrinol Metab
December 2025
Department of Endocrinology, Scientific Services, USV Pvt. Ltd, Mumbai, Maharashtra, India.
Background: Co-occurrence of type 2 diabetes mellitus (T2DM) and heart failure (HF) elevates the risk of morbidity and mortality. Recent research emphasizes treatment strategies that go beyond glycemic control to enhance heart function.
Aim: To assess the effectiveness and safety of the fixed-drug combination of dapagliflozin and sitagliptin (FDC D/S) in T2DM patients with HF.
Biomed Eng Lett
September 2025
Department of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, China.
Abstract: Hypertrophic cardiomyopathy (HCM) is a common hereditary heart disease and is the leading cause of sudden cardiac death in adolescents. Septal hypertrophy (SH) and apical hypertrophy (AH) are two common types. The former is characterized by abnormal septal myocardial thickening and the latter by left ventricular apical hypertrophy, both of which significantly increase the risk of heart failure, arrhythmias, and other serious complications.
View Article and Find Full Text PDFJ Thorac Cardiovasc Surg
September 2025
Deparment of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. Electronic address:
Objective: To evaluate the impact of CT planning on surgical myectomy outcomes in patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) and/or mid-cavity obstruction, by comparing these outcomes with those of conventional surgical myectomy.
Methods: This prospective cohort study included patients who underwent surgical septal myectomy for HCM with LVOT and/or mid-cavity obstruction between January 2019 and May 2024 at a single tertiary center. In the CT-planned myectomy group, an expert radiologist simulated the target myectomy site through a series of post-processing methods to plan the surgical approach, provide a surgeon's view that closely resembles the actual perspective in the operating room, and present the target myectomy volume.